Your session is about to expire
← Back to Search
Galunisertib + Paclitaxel for Triple Negative Breast Cancer
Study Summary
This trial is testing Galunisertib + Paclitaxel to treat patients with androgen receptor negative or triple negative breast cancer.
- Triple Negative Breast Cancer
- Breast Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Treatment (Paclitaxel, Galunisertib)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What other examinations have been conducted to assess the efficacy of Galunisertib?
"Galunisertib is the focus of 836 active clinical trials, with 227 being in Phase 3. In terms of geographical availability, Woolloongabba, Queensland serves as a hub for many of these studies while 45717 sites around the world are conducting research on Galunisertib."
What is the maximum capacity of participants in this medical experiment?
"Unfortunately, this clinical trial does not appear to be currently accepting patients. It was initially listed on the 3rd of March 2016 and last edited 12th of May 2022. Alternately, there are 4569 trials recruiting participants with her2/neu negative and 836 studies enlisting individuals for Galunisertib at this time."
What therapeutic issues is Galunisertib most frequently prescribed to address?
"Galunisertib is capable of treating neoplasm metastasis, kaposi sarcoma, and advance directives."
Are there any additional participants being sought for the experiment?
"This medical trial is no longer actively accepting participants. It was first posted on March 1st, 2016 and last updated on May 12th, 2022. For those still searching for clinical trials to join, there are currently 4569 studies recruiting patients with HER2/neu negative conditions, as well as 836 active studies looking for Galunisertib patients."
What are the risk factors associated with Galunisertib treatment?
"Due to the limited data available, Galunisertib has been given a score of 1 in terms of its safety when evaluated by Power. It is currently undergoing Phase One clinical trials for further evaluation."
Share this study with friends
Copy Link
Messenger